Parkinson’s Disease Medication Safety in the Inpatient Cohort of a Tertiary Centre
Objective: Our study aimed to determine the accuracy of initial prescribing on hospital admission and the subsequent timing of administration of Parkinson’s disease (PD) medications…The responsiveness of arm swing to dopaminergic medication in Parkinson’s disease depends on task complexity
Objective: The aim of this study is to analyse the responsiveness of arm swing during walking to dopaminergic medication in patients with Parkinson’s disease. Background:…Effects of dopaminergic medication on reinforcement learning in Parkinson’s disease depend on depressive symptoms
Objective: To investigate the effect of depression and dopaminergic medication on reinforcement learning (RL) in Parkinson’s disease. Background: Dopaminergic medication in PD is known to…DAT-IQ improves power to detect longitudinal change in DaT deficit in SURE-PD3
Objective: DATIQ has been developed as a novel analytical approach to improve the sensitivity and statistical efficiency of dopamine transporter (DaT) SPECT quantification over previously…Is dopamine replacement therapy an addictive drug?
Objective: To identify common clinical and imaging abnormalities in Parkinson's disease patients and heroin-dependent patients compared with healthy controls in order to better understand the pathophysiology…Behavioral effects of stimulated dopamine release and D2-like receptor displacement in Parkinson’s patients with impulse control disorder
Objective: To evaluate behavioral effects of stimulated dopamine (DA) release in Parkinson’s disease (PD) by assessing D2/3 receptor (DA-R) displacement on PET imaging Background: Previous…Three-year safety and clinical outcomes from the PD-1101 trial of AADC gene therapy for advanced Parkinson’s disease
Objective: To present preliminary 3-year data from the PD-1101 trial of VY-AADC01 for advanced Parkinson’s disease (PD) with motor fluctuations. Background: This 3-year phase 1b…AADC gene therapy administered via a posterior approach: 18-month results from the PD-1102 trial in advanced Parkinson’s disease
Objective: To report 18-month safety and clinical outcomes from a phase 1, open-label trial of VY-AADC01 (NBIb-1817) for Parkinson’s disease (PD) patients with motor fluctuations.…A Case of Improved Psychotic Depression and Motor Symptoms in Parkinson’s Disease following Electroconvulsive Therapy (ECT)
Objective: To describe a case of motoric, affective, and psychotic symptoms improving in PD following ECT. Background: Parkinson’s disease (PD) is a neurodegenerative disease caused…Impedance Doesn’t Change with Levodopa Treatment
Objective: We aimed to evaluate the impedance of patients on their best ON/worst OFFs with levodopa, assuming that the level of dopamine at electrode’s vicinity…
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 24
- Next Page »